Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must give written informed consent by parent or guardian~* Male or female subjects, \> 6 - 17 years~* Patients must have endoscopic or radiographic confirmed Crohn's Disease.~* Patients must have a Pediatric Crohn's Disease Activity Index (PCDAI) of at least 31.~Exclusion Criteria:~* Adolescent women of childbearing potential and / or sexually active unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide), and willing and able to continue contraception for 3 months after the completion of the study.~* Adolescent women who are pregnant or breastfeeding~* Subjects with an ostomy or ileocolic anastomosis from surgery as these operations interfere with the PCDAI assessment~* Subjects taking tacrolimus, cyclosporin, mycophenolate, or anti-TNF-α therapy must be discontinued 4 weeks prior to study initiation.~* Patients with abnormal liver function tests~* Prednisone greater than 10 mg or \> 0.2 mg/kg orally

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
- Naltrexone (Type: EXPERIMENTAL): Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.

Based on this trial design, predict the completion outcome and termination type (if applicable).